ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1.

Karin Enell Smith Sara FritzellAnneli NilssonKarin BarchanAnna RosénLena SchultzLaura VarasAnna SällNadia RoseMaria HåkanssonLaura von Schantz Peter Ellmark

Published in: Cancer immunology, immunotherapy : CII (2023)

These preclinical data demonstrate a strong safety profile of ATOR-1017, together with its potent therapeutic effect as monotherapy and in combination with anti-PD1, supporting further clinical development of ATOR-1017.

Keyphrases

electronic health record
growth factor
big data
open label
randomized controlled trial
clinical trial
mesenchymal stem cells